Dompé Looks Beyond In-Licensing
Executive Summary
Mid-sized Italian drug firm Dompé has made its name as an astute local marketer. Yet the company is now talking up its in-house R&D programs, acknowledging that a pure in-licensing model may not work forever.
You may also be interested in...
Chiesi's First Step Into Germany
Buying a foothold in Germany filled an important gap in Chiesi's European expansion strategy. But the privately owned Italian group may have to loosen up its dealmaking style to continue to clinch the deals it needs.
Pandemic Spotlights Tensions Between Profit And Philanthropy
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Virtual Health Care: Where Does This Leave Pharma Marketing?
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports